Anticonvulsant Activities of 4-benzylidene-6-(4-methyl-phenyl)-4,5-dihydropyridazin-(2H)-ones and 4-benzylidene-6-(4-chloro-phenyl)-4,5-dihydropyridazin-(2H)-ones

Table 2: Anticonvulsant activity of 6-(p-Chloro/p-methyl/m-nitro-phenyl)-4-arylidene-4,5-dihydropyridazin-3(2H)-one compounds (3a-m) against isoniazid (INH) induced method.

S. No.	Groups	Onset of convulsion (sec)	No. of convulsion	Recovery (%)
1	Compd 3a	36.2±6.27 ^γa	2.5±0.22	80
2	Compd 3b	47±4.50 ^γc	2.8±0.25	80
3	Compd 3c	48.6±3.87^γc	2.5±0.24	60
4	Compd 3d	34.6±3.24^γ	2.4±0.36	100
5	Compd 3e	35.2±6.98^γ	2.6±0.35	100
6	Compd 3f	42.6±2.62 ^γc	2.0±0.32	80
7	Compd 3g	46.8±2.06^γc	2.4±0.34	80
8	Compd 3h	48±1.82 ^γc	2.4±0.26	80
9	Compd 3i	47.6±4.24 ^γc	2.2±0.24	60
10	Compd 3j	48.2±4.18 ^γc	2.6±0.18	100
11	Sod. VPA	130.2 ± 2.15	1.4±0.22	100
12	PHT sod.	0.00	0.00	100
13	Control	26.16±.094	3.2±0.20	00

Standard drug: PHT sodium (25mg/kg) and Sodium VPA (100mg/kg), Tested drugs: (50mg/kg), Control group: INH-250mg/kg+0.5 % CMC in distilled water; n=5 (No. of animals in each group); *Value represents mean ± S.E.M. ^cP< 0.001 when compared to control group ^γP< 0.001 when compared to standard drug sodium VPA.